

PTO/SB/30 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Request  
For  
Continued Examination (RCE)  
Transmittal**Address to:  
Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Application Number	10/761,636
Filing Date	January 21, 2004
First Named Inventor	Bernard Frank Bishop
Art Unit	1623
Examiner Name	Traviss C. McInerney
Attorney Docket Number	PC22004B

FAX RECEIVED

SEP 15 2006

OFFICE OF PETITIONS

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

- a. ☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

- i. ☐ Consider the arguments in the Appeal Brief or Rely Brief previously filed on \_\_\_\_\_

- ii. ☐ Other \_\_\_\_\_

- b. ☒ Enclosed

- i. ☐ Amendment/Reply

- iii. ☒ Information Disclosure Statement (IDS)

- ii. ☐ Affidavit(s)/ Declaration(s)

- iv. ☐ Other \_\_\_\_\_

2. **Miscellaneous**

- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)

- b. ☐ Other \_\_\_\_\_

3. **Fees**

The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

The Director is hereby authorized to charge the following fees, or credit any overpayments, to

- a. ☒ Deposit Account No. 21-0718 The total amount charged is \$ 790.00

- i. ☒ RCE fee required under 37 CFR 1.17(e)

- ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17). A \_\_\_\_\_ month extension is requested.


- iii. ☐ Other \_\_\_\_\_

- b. ☐ Check in the amount of \$ \_\_\_\_\_ enclosed

- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name (Print/Type)	Thomas A. Wootton	Registration No. (Attorney/Agent)	35,004
Signature		Date	September 15, 2006

**CERTIFICATE OF MAILING OR TRANSMISSION**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type)	Jennifer S. Naylor	Date	September 15, 2006
Signature			

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

09/18/2006 CKHLOK 00000023 210718 10761636

02 FC:1801 790.00 DA

**PATENT**/Docket No. PC22004B

Appl. No. 10/761,636

Filing Date: January 21, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**FAX RECEIVED**

Art Unit : 1623

SEP 15 2006

Examiner : Traviss C. McIntosh III

**OFFICE OF PETITIONS**

Applicant(s) : Bernard Frank Bishop

Serial Number : 10/761,636

Filed : January 21, 2004

For : AVERMECTIN AND PRAZIQUANTEL COMBINATION THERAPY

Commissioner of Patents

P.O. Box 1450

Alexandria, VA 22313-1450


**REQUEST FOR CONTINUED EXAMINATION**

Sir:

Applicant hereby files a Request for Continued Examination of the above-referenced patent application in compliance with § 1.114. Subsequent to the payment of the issue fee on August 7, 2006, Applicant received a communication from a foreign examining authority citing additional prior art resulting from the foreign examination. Therefore, the present Request for Continued Examination is being filed in order to have the newly discovered art examined.

Attached is a Request for Continued Examination (RCE) Transmittal authorizing the payment of the \$790.00 fee. Please charge any additional fees or credit any overpayments to Deposit Account Number 21-0718.

Respectfully submitted,



Thomas A. Wootton, Attorney

Registration No. 35,004

Date: 15 September 2006

Pharmacia & Upjohn Company

7000 Portage Road

Kalamazoo, Michigan 49001

Telephone No. (269) 833-7914 or (269) 833-9500

Telefax No. (269) 833-8897 or (269) 833-2316

FORM AMEND

Rev. 5/27/03